Related references
Note: Only part of the references are listed.In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Woojun Kim et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens
Ditte E. Jaehger et al.
SCIENTIFIC REPORTS (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
Daniela G. M. Tantalo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment
Elsa Quintana et al.
CANCER RESEARCH (2020)
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Alireza Labani-Motlagh et al.
FRONTIERS IN IMMUNOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
Hao Chen et al.
ONCOGENE (2020)
Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
Nikolaos Patsoukis et al.
COMMUNICATIONS BIOLOGY (2020)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Mingxia Zhao et al.
ACTA PHARMACEUTICA SINICA B (2019)
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Charlene Niogret et al.
FRONTIERS IN IMMUNOLOGY (2019)
Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice
Andrew Kroetsch et al.
MABS (2019)
In Vivo PET Tracking of 89Zr-Labeled Vγ9Vδ2 T Cells to Mouse Xenograft Breast Tumors Activated with Liposomal Alendronate
Francis Man et al.
MOLECULAR THERAPY (2019)
T cells loaded with magnetic nanoparticles are retained in peripheral lymph nodes by the application of a magnetic field
Laura Sanz-Ortega et al.
JOURNAL OF NANOBIOTECHNOLOGY (2019)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Li Tang et al.
NATURE BIOTECHNOLOGY (2018)
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S. Wong et al.
NATURE MEDICINE (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Leila Dardaei et al.
NATURE MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Defining Memory CD8 T Cell
Matthew D. Martin et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cell-mediated delivery of synthetic nano- and microparticles
Maxime Ayer et al.
JOURNAL OF CONTROLLED RELEASE (2017)
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Tyrel T. Smith et al.
NATURE NANOTECHNOLOGY (2017)
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Daniela Schmid et al.
NATURE COMMUNICATIONS (2017)
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Designing nanomedicine for immuno-oncology
Wen Jiang et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes
Laura Wayteck et al.
BIOMATERIALS (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm et al.
NATURE REVIEWS MATERIALS (2016)
Regulation of T cell signalling by membrane lipids
Wei Wu et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Bonnie Huang et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
Jing Li et al.
CANCER RESEARCH (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis
Tao Zhang et al.
SCIENTIFIC REPORTS (2013)
Quantitative structure - property relationship modeling of remote liposome loading of drugs
Ahuva Cern et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Arginine-rich cell-penetrating peptides
Nathan Schmidt et al.
FEBS LETTERS (2010)
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
Matthias T. Stephan et al.
NATURE MEDICINE (2010)
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Gordon Chan et al.
CANCER AND METASTASIS REVIEWS (2008)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
Mikael J. Pittet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associllited T cells
Michael R. Nazareth et al.
JOURNAL OF IMMUNOLOGY (2007)
Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient
Andreas Fritze et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2006)
T lymphocytes as potential therapeutic drug carrier for cancer treatment
U Steinfeld et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2
M Gavrieli et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Response of naive and memory CD8+ T cells to antigen stimulation in vivo
H Veiga-Fernandes et al.
NATURE IMMUNOLOGY (2000)
Share Paper
